The Ensign Group (ENSG) stock outlook 2026. A deep look at its decentralized operating moat, disciplined turnaround M&A, skilled-nursing and post-acute demand from aging demographics, plus Medicaid, Medicare, and staffing risks.
Chemed (CHE) 2026 stock analysis: the odd-couple model of VITAS hospice and Roto-Rooter plumbing, Medicare reimbursement and per-beneficiary cap risk, disciplined buyback-driven per-share compounding, labor inflation, and housing-cycle sensitivity.
DVA (DaVita) stock outlook for 2026. A qualitative deep dive into the US dialysis clinic duopoly, how the commercial-versus-Medicare payer mix drives margins, the long-run volume risks from GLP-1s, kidney transplants and home dialysis, plus Berkshire ownership and the aggressive buyback engine.